Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Mink Therapeutics Inc
INKTMiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. Address: 149 Fifth Avenue, New York, NY, United States, 10010
Analytics
Objectif de Cours de WallStreet
8 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés INKT
Analyse des dividendes INKT
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes INKT
Valorisation des titres INKT
financières INKT
Résultats | 2019 | Dynamique |